COMPARATIVE ANALYSIS OF THE EFFICACY OF ANGIOGENESIS INHIBITORS TREATMENT FOR WET AGE-RELATED MACULAR DEGENERATION, DEPENDING ON SEVERITY OF THE DISEASE
DOI:
https://doi.org/10.31288/oftalmolzh201313036Keywords:
вікова дегенерація макули, ранібізумаб, пегаптоніб натріяAbstract
Treatment of patients with mild forms of wet AMD may as ranibizumab and pegaptonib sodium, but ranibizumab preferred therapy of severe wet AMD.
References
1.Король А. Р. Классификация экссудативной формы возрастной макулярной дегенерации по степени тяжести / А. Р. Король, Е. И. Драгомирецкая, Т. Б. Кустрин // Сучасні медичні технології. - 2012. - № 6. - (в печати).
2.Янковой А. Г. Многомерный анализ в системе STATISTICA / А. Г. Янковой // Одесса: OPTIMUM. - 2001. - 216 c.
3.Brown D. M. Ranibizumab versus verteporfm for neovascular age-related macular degeneration / D. M. Brown, P. K. Kaiser, M. Michels et al // N. Eng. J. Med. - 2006. - Vol. 355. - P. 1432- 1444.https://doi.org/10.1056/NEJMoa062655
4.Brown D. M. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular de-generation: two-year results of the ANCHOR study / D. M. Brown, M. Michels, P. K. Kaiser et al // Ophthal-mology. - 2009. - Vol. 116. - P. 57- 65.https://doi.org/10.1016/j.ophtha.2008.10.018
5.Ding X. Molecular pathology of age-related macular degeneration / X. Ding, M. Patel, C. C. Chan // Prog. Retin. EyeRes. - 2009. - Vol. 28. - № 1. - P. 1-18.
https://doi.org/10.1016/j.preteyeres.2008.10.001
6.Gaudreault J. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration / J. Gaudreault, D. Fei, J. Rusit et al // Invest. Ophthalmol. Vis. Sci. - 2005. - Vol. 46. - P. 726- 733.https://doi.org/10.1167/iovs.04-0601
7.Gonzales CR. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis / CR Gonzales, VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group // Retina. - 2005. - Vol. 25. - P. 815- 827.https://doi.org/10.1097/00006982-200510000-00001
8.Rosenfeld P. J. Ranibizumab for neovascular age-related macular degeneration / P. J. Rosenfeld, D. M. Brown, J. S. Heier et al // N. Eng. J. Med. - 2006. - Vol. 355. - P. 1419-1431.https://doi.org/10.1056/NEJMoa054481
9.Singh RP. Role of ranibizumab in management of macular degeneration / RP Singh, PK Kaiser // Indian J Ophthal-mol. - 2007. - Vol. 55, № 6. - P. 421- 425.https://doi.org/10.4103/0301-4738.36475
Downloads
Published
Issue
Section
License
Copyright (c) 2013 A. R. Korol
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
